New drug combo aims to wipe out lingering blood cancer cells
NCT ID NCT05317936
Summary
This study tested if adding a new drug called pirtobrutinib to an existing treatment (venetoclax) could help eliminate the last traces of cancer in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. It was for adults who had already been on venetoclax for at least a year but still had detectable cancer cells. The main goal was to see if the combination could make the cancer undetectable by very sensitive tests. The study was terminated early after enrolling only 3 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.